BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Total Non-current Assets
All assets not expected to be converted to cash within one year.
BioAge Labs, Inc.NASDAQ: BIOA
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 69.6% from a year ago
Total non-current assets stood at $5.79M at the end of Q1 FY2026, down 69.6% from a year earlier and down 28.4% from the prior quarter. Over 3 fiscal years it compounded at +172.8% a year.
Context
- Total non-current assets amounted to 1.5% of total assets at the end of Q1 FY2026, down 4.1 pp from a year earlier.
- Total non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -69.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 8.1M USD
- Year-over-year change
- +615.8%
- 3-year CAGR
- +172.8%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.1M | +615.8% |
| FY2024 | 2024-12-31 | 1.13M | +83.0% |
| FY2023 | 2023-12-31 | 618K | +54.9% |
| FY2022 | 2022-12-31 | 399K | — |
Total Non-current Assets vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -69.6% is the lowest of 9, against a peer median of -40.7%.
- Total non-current assets amounts to 1.5% of total assets for BIOA, versus a peer median of 33.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$589.27M CAD | -5.4% | -15.5% | 52.7% | |
| Mar 2026 | CA$204.16M CAD | -45.1% | -23.0% | 33.9% | |
| Dec 2025 | $149.89M USD | — | — | 64.6% | |
| Mar 2026 | $122.67M USD | -43.3% | -18.6% | 31.0% | |
| Mar 2026 | $66.98M USD | -9.8% | -8.8% | 67.9% | |
| Mar 2026 | $46.96M USD | -47.1% | -1.0% | 42.5% | |
| Mar 2026 | $25.83M USD | -15.4% | +47.7% | 17.4% | |
| Mar 2026 | $21.27M USD | -45.2% | -47.6% | 14.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $5.79M USD | -69.6% | +172.8% | 1.5% |
| Mar 2026 | $3.88M USD | -38.0% | -9.9% | 1.5% | |
| Peer median (excluding BIOA) | — | -40.7% | -12.7% | 33.9% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.